For decades, FSGS management meant RAS blockade, off-label immunosuppression, and hope. 2026 changed that: sparsentan became the first FDA-approved drug for FSGS in April, and now a new JASN analysis suggests finerenone may slow eGFR loss in FSGS too.
•
Design: Prespecified analysis of FIND-CKD — the
phase 3, double-blind RCT of finerenone vs placebo in 1,584 adults with non-diabetic
CKD, on top of maximally tolerated RAS blockade, followed 32 months. FSGS cohort: 215 patients (of 903 with
glomerular disease) — 108 primary, 107 secondary; 167 biopsy-proven. Mean
baseline eGFR ~45 mL/min/1.73 m².
Results:
|
Outcome |
Finerenone
vs placebo |
|
Total eGFR slope (32 mo) |
+1.3 mL/min/1.73 m²/yr slower decline (95% CI
0.5–2.2; P = .002) |
|
eGFR slope, biopsy-proven FSGS (n = 167) |
+1.4 mL/min/1.73 m²/yr |
|
Placebo eGFR decline |
~4–5 mL/min/1.73 m²/yr |
|
UPCR at 12 months |
−41% (95% CI 26–53%) |
|
UPCR < 700 mg/g at 12 months |
OR 6.8 (95% CI 3.0–17.2) |
|
Kidney composite (≥57% eGFR decline or kidney failure) |
HR 0.58 (95% CI 0.30–1.15) — not significant |
|
Hyperkalemia-related AEs |
15% vs 20% |
Notable: the eGFR-slope benefit in FSGS (1.3) is
nearly double that of the overall FIND-CKD population (0.7 mL/min/1.73 m²/yr).
This is good as it is a randomized, placebo-controlled, prespecified, a surprisingly large FSGS cohort, and a hard-ish endpoint (eGFR slope) — something DUPLEX did not achieve for sparsentan at 108 weeks despite superior proteinuria reduction vs irbesartan.
Subgroup analysis; the composite outcome was underpowered and not significant.
•
Open question: sequencing — SGLT2i first?
Finerenone? ERA plus finerenone? Heerspink has called for a dedicated (e.g.,
SMART-design) trial.
FSGS therapies: approval status (as of November 2026)
|
Drug |
Class |
US
status for FSGS |
Key
evidence |
Practical
notes |
|
Sparsentan (Filspari) |
Dual endothelin-A / AT1 receptor antagonist (DEARA) |
FDA full approval, Apr 13, 2026 — to reduce
proteinuria in patients ≥8 yrs with FSGS without nephrotic syndrome.
First and only FSGS-approved drug. |
DUPLEX (phase 3), DUET (phase 2) |
Replaces (not added to) ACEi/ARB. REMS for
hepatotoxicity/embryo-fetal toxicity. Also approved for IgAN. |
|
Finerenone (Kerendia) |
Non-steroidal MRA |
Not approved for FSGS. sNDA for non-diabetic CKD
under FDA review. Approved for CKD + T2D, CKD + T1D (Sep 2026), HFmrEF/HFpEF. |
FIND-CKD FSGS analysis (JASN 2026) |
Add-on to RASi; monitor K⁺. |
|
Dapagliflozin / empagliflozin |
SGLT2 inhibitor |
Approved for CKD broadly (not FSGS-specific) |
DAPA-CKD / EMPA-KIDNEY subgroups |
Effect in FSGS modest/uncertain; reasonable background
therapy. |
|
Apecotrep |
TRPC6 inhibitor |
Investigational — phase 3 recruiting |
Phase 2 (12 wk): −40% proteinuria vs placebo at 20 mg |
Likely an add-on rather than standalone. |
|
APOL1 inhibitors |
APOL1 channel inhibition |
Investigational |
Ongoing trials in APOL1-mediated kidney disease |
Genotype-targeted (APOL1 high-risk). |
No comments:
Post a Comment